Journal
NEUROLOGY
Volume 79, Issue 15, Pages 1570-1577Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31826e2696
Keywords
-
Categories
Funding
- NIH [P50 AG016574, U01 AG006786, U01 AG037526, K01 MH068351, RO1 AG011378, K01 AG028573]
- NIH/NIA
- Baxter
- Elan Pharmaceuticals
- Forest Pharmaceuticals
- NIH
- GE Healthcare
- Siemens Molecular Imaging
- NIH (NIA, NCI)
- MN Partnership for Biotechnology and Medical Genomics
- Leukemia & Lymphoma Society
- Abbott Research Labs
- Robert Wood Johnson Foundation
- European Union Regional Development Fund
- Cephalon, Inc.
- Alzheimer's Association
- Center for Inherited Disease Research
- Baxter International Inc.
- Allon Therapeutics, Inc.
- Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation
- Alexander Family Alzheimer's Disease Research Professorship, GE Healthcare [R01 AG034676]
Ask authors/readers for more resources
Objectives: Secondary prevention trials in subjects with preclinical Alzheimer disease may require documentation of brain amyloidosis. The identification of inexpensive and noninvasive screening variables that can identify individuals who have significant amyloid accumulation would reduce screening costs. Methods: A total of 483 cognitively normal (CN) individuals, aged 70-92 years, from the population-based Mayo Clinic Study of Aging, underwent Pittsburgh compound B (PiB)-PET imaging. Logistic regression determined whether age, sex, APOE genotype, family history, or cognitive performance was associated with odds of a PiB retention ratio >1.4 and >1.5. Area under the receiver operating characteristic curve (AUROC) evaluated the discrimination between PiB-positive and -negative subjects. For each characteristic, we determined the number needed to screen in each age group (70-79 and 80-89) to identify 100 participants with PiB > 1.4 or >1.5. Results: A total of 211 (44%) individuals had PiB >1.4 and 151 (31%) >1.5. In univariate and multivariate models, discrimination was modest (AUROC similar to 0.6-0.7). Multivariately, age and APOE best predicted odds of PiB > 1.4 and >1.5. Subjective memory complaints were similar to cognitive test performance in predicting PiB >1.5. Indicators of PiB positivity varied with age. Screening APOE epsilon 4 carriers alone reduced the number needed to screen to enroll 100 subjects with PIB >1.5 by 48% in persons aged 70-79 and 33% in those aged 80-89. Conclusions: Age and APOE genotype are useful predictors of the likelihood of significant amyloid accumulation, but discrimination is modest. Nonetheless, these results suggest that inexpensive and noninvasive measures could significantly reduce the number of CN individuals needed to screen to enroll a given number of amyloid-positive subjects. Neurology (R) 2012; 79: 1570-1577
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available